Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | sphingosine 1-phosphate lyase | 0.0106 | 0.5 | 0.5 |
Echinococcus granulosus | sphingosine 1 phosphate lyase 1 | 0.0106 | 0.5 | 0.5 |
Entamoeba histolytica | s phingosine-1-phosphate lyase 1, putative | 0.0106 | 0.5 | 0.5 |
Trypanosoma brucei | sphingosine 1-phosphate lyase, putative | 0.0106 | 0.5 | 0.5 |
Schistosoma mansoni | sphingosine phosphate lyase | 0.0106 | 0.5 | 0.5 |
Echinococcus multilocularis | sphingosine 1 phosphate lyase 1 | 0.0106 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0106 | 0.5 | 0.5 |
Trypanosoma cruzi | sphingosine 1-phosphate lyase, putative | 0.0106 | 0.5 | 0.5 |
Trypanosoma cruzi | sphingosine 1-phosphate lyase, putative | 0.0106 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 1.2 | Mean collapse time after pretreatment with compound and mepyramine divided by mean collapse time of mepyramine-dosed control animals at 50 mg/kg po dose | ChEMBL. | 3612683 |
Activity (functional) | = 2.5 | Mean collapse time after pretreatment with compound divided by mean collapse time of untreated control animals at 50 mg/kg po dose | ChEMBL. | 3612683 |
Inhibition (functional) | NT 0 % | Inhibition of histamine release from sensitized guinea pig chopped lung, upon antigen challenge at 10 ug/mL. | ChEMBL. | 3612683 |
Inhibition (functional) | = 22 % | Inhibition of slow reacting substance of anaphylaxis (SRS-A) release from sensitized guinea pig chopped lung upon antigen challenge at 10 ug/mL | ChEMBL. | 3612683 |
Time (functional) | = 2 hr | Time of dosing of compound before antigen challenge in conscious sensitized guinea pig at 50 mg/kg po dose | ChEMBL. | 3612683 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.